Doxorubicin Hydrochloride Injection, Solution
Product Images NDC 68083-248

9 FDA label images from Gland Pharma Limited · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Doxorubicin Hydrochloride (NDC 68083-248). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gland Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Doxorubicin-spl-100-ml-carton (Doxorubicin Spl 100 mL Carton)

Doxorubicin-spl-100-ml-carton (Doxorubicin Spl 100 mL Carton)
Packaging label for Doxorubicin Hydrochloride Injection, USP 2 mg/mL (200 mg/100 mL) in a 100 mL multi-dose vial. The label specifies intravenous use only and highlights that this is a cytotoxic agent. Manufactured by Gland Pharma Limited, India. The label includes dosage information, storage instructions, and a barcode.*
FDA Label Image

Doxorubicin-spl-100-ml-vial (Doxorubicin Spl 100 mL Vial)

Doxorubicin-spl-100-ml-vial (Doxorubicin Spl 100 mL Vial)
Doxorubicin Hydrochloride Injection, USP 200 mg/100 mL (2 mg/mL) in a 100 mL multi-dose vial. The label states it is for intravenous use only and contains a caution that this is a cytotoxic agent. It includes storage instructions, manufacturer information (Gland Pharma Limited), and a barcode.*
FDA Label Image

Doxorubicin-spl-25-ml-vial (Doxorubicin Spl 25 mL Vial)

Doxorubicin-spl-25-ml-vial (Doxorubicin Spl 25 mL Vial)
Label for Doxorubicin Hydrochloride Injection, USP 50 mg/25 mL (2 mg/mL) intravenous solution by Gland Pharma Limited. The 25 mL single-dose vial label indicates it is for intravenous use only with a caution for cytotoxicity. The label contains dosage concentration, usage instructions, and a barcode.*
FDA Label Image

Doxorubicin-spl-5-ml-carton (Doxorubicin Spl 5 mL Carton)

Doxorubicin-spl-5-ml-carton (Doxorubicin Spl 5 mL Carton)
Box packaging label for Doxorubicin Hydrochloride Injection, USP 10 mg/5 mL (2 mg/mL) intravenous solution by Gland Pharma Limited. Label indicates a 5 mL single-dose vial, cautions about cytotoxicity, and includes storage instructions and warnings about severe cellulitis and tissue necrosis risk with extravasation.*
FDA Label Image

Doxorubicin-spl-struc (Doxorubicin Spl Struc)

Doxorubicin-spl-struc (Doxorubicin Spl Struc)
Chemical structure of Doxorubicin Hydrochloride, showing its detailed molecular arrangement with formula C27H29NO11•HCl and molecular weight 579.99.*
FDA Label Image

Doxorubicin-spl-25-ml-carton (Doxorubicin Spl 25 mL Carton)

Doxorubicin-spl-25-ml-carton (Doxorubicin Spl 25 mL Carton)
Packaging label for Doxorubicin Hydrochloride Injection, USP, 50 mg/25 mL (2 mg/mL) solution for intravenous use. The label includes the drug name, strength, single-dose vial size (25 mL), storage instructions (refrigeration between 2° to 8°C), and caution as a cytotoxic agent. It is manufactured by Gland Pharma Limited.*
FDA Label Image

Doxorubicin-spl-5-ml-vial (Doxorubicin Spl 5 mL Vial)

Doxorubicin-spl-5-ml-vial (Doxorubicin Spl 5 mL Vial)
Label for Doxorubicin Hydrochloride Injection, USP 10 mg/5 mL (2 mg/mL) solution for intravenous use, 5 mL single-dose vial. The label includes dosing concentration, caution indicating cytotoxic agent status, manufacturer Gland Pharma Limited, and storage and safety information.*
FDA Label Image

Doxorubicin-spl-graph1 (Doxorubicin Spl Graph1)

Doxorubicin-spl-graph1 (Doxorubicin Spl Graph1)
A forest plot chart showing hazard ratios with 95% confidence intervals for various clinical trials comparing Doxorubicin-based treatments versus CMF. The trials include NSABP B-15, SECSG 2, ONCOFRANCE, SE Sweden BCG A, NSABC Israel Br0283, and Austrian BCSG 3. The overall combined result from six studies is represented by a diamond shape at the bottom. The chart indicates boundaries for non-inferiority with CMF treatment.*
FDA Label Image

Doxorubicin-spl-graph2 (Doxorubicin Spl Graph2)

Doxorubicin-spl-graph2 (Doxorubicin Spl Graph2)
A forest plot comparing hazard ratios with 95% confidence intervals from multiple clinical trials evaluating Doxorubicin based treatments versus CMP. Trials such as NSABP B-15, SECSG 2, ONCOFRANCE, and others are listed on the y-axis, while the x-axis shows hazard ratios ranging from 0 to 20, indicating relative treatment efficacy and safety outcomes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.